Raloxifene (Evista), a "designer estrogen" from Lilly

July 1997

There's lots of interest in raloxifene (Evista), a "designer estrogen" from Lilly. It has been covered on TV, in the news, etc.

It's being tested to prevent osteoporosis in postmenopausal women...as an alternative to using estrogen.

Raloxifene is a "selective estrogen receptor modulator"...it has both estrogen agonist AND antagonist effects.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote